NEU 2.81% $18.65 neuren pharmaceuticals limited

Ann: Comment on research report, page-87

  1. 62 Posts.
    lightbulb Created with Sketch. 10

    Speaking from recent experience of being invested in a company that was recently subject to a Culpers short seller report, I’ve found their analysis highly lacking and their track record quite abysmal. In the case of NEU, I’m sure there’s a lot of long-term holders who see this as none other than a good buying opportunity. Much of the panic selling is no doubt being caused by those who bought in over the last 12-18 months and by all accounts probably don’t know much about what they’re holding, the strength of the science or the calibre of NEU’s management team. Just my 2 cents worth but I topped up again today and will be taking any further drawdowns as further opportunities to add to my position.


    For those interested, take a look at GigaCloud. The short report came out on 28th September last year. See where the share price is today….

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.